Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure

[1]  S. Byun,et al.  Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy , 2022, Prostate International.

[2]  S. Hong,et al.  Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer , 2022, Prostate international.

[3]  Mingxing Huang,et al.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis , 2021, Frontiers in Oncology.

[4]  A. D'Amico,et al.  Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. , 2021, European urology oncology.

[5]  J. Raman,et al.  Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry , 2020, Prostate international.

[6]  C. Stief,et al.  Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis , 2020, Cancers.

[7]  W. Vogel,et al.  Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging , 2020, The Journal of Nuclear Medicine.

[8]  C. Zechmann,et al.  Detection Rate of 18F-Fluorethylcholine-PET/CT in relation to PSA Value in PCA Patients Referred with Biochemical Relapse , 2020, Contrast media & molecular imaging.

[9]  G. Treglia,et al.  Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses , 2020, Cancers.

[10]  J. Jiménez-Hoyuela,et al.  Usefulness of 18F-Choline Positron Emission Tomography - Computed Tomography in the therapeutic management of patients with biochemical recurrence of prostate adenocarcinoma treated with brachytherapy. , 2020, Actas urologicas espanolas.

[11]  O. Schillaci,et al.  10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients. , 2020, Clinical nuclear medicine.

[12]  Y. Kyung,et al.  Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer , 2020, Journal of Cancer Research and Clinical Oncology.

[13]  J. Kim,et al.  Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015 , 2019, Yonsei medical journal.

[14]  M. H. Poulsen,et al.  18F-Fluoromethylcholine-positron emission tomography/computed tomography for diagnosing bone and lymph node metastases in patients with intermediate- or high-risk prostate cancer , 2019, Prostate international.

[15]  C. Buchpiguel,et al.  Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[16]  N. Vasdev,et al.  Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review , 2019, Therapeutic advances in urology.

[17]  G. Pignot,et al.  "Real-world" evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy. , 2019, Urologic oncology.

[18]  F. Bertagna,et al.  18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer , 2018, Endocrine.

[19]  J. Talbot,et al.  18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study , 2018, PloS one.

[20]  H. Tam,et al.  Clinical PET Imaging in Prostate Cancer-Erratum. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[21]  J. Ciezki,et al.  Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. , 2016, International journal of radiation oncology, biology, physics.

[22]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[23]  Choung-Soo Kim,et al.  Epidemiology of prostate cancer in South Korea , 2015, Prostate international.

[24]  D. Rubello,et al.  Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.

[25]  M. Coel,et al.  Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging , 2012, Annals of Nuclear Medicine.

[26]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  P. Carroll,et al.  A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. , 2008, The Journal of urology.

[28]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.